AGC | Arabian Gulf Capital

WEEKLY IDEA

PFIZER INC

WEEKLY IDEA

15 June 2026

AGC
Arabian Gulf Capital

BUY PFIZER INC (PFE US EQUITY) THE NEXT GENERATION OF GLOBAL HEALTHCARE

Pfizer is one of the world's largest biopharmaceutical companies, developing innovative medicines and vaccines across oncology, immunology, internal medicine, rare diseases, and infectious diseases. With operations in more than 180 countries, the company combines global research capabilities, large-scale manufacturing, and an extensive commercial network to develop and distribute therapies worldwide.

Following the normalization of pandemic-related revenues, Pfizer has been repositioning its business through investments in oncology, obesity, and next-generation therapeutics, while integrating artificial intelligence across research and operations to improve productivity and accelerate innovation. Backed by one of the industry's largest commercial platforms and a broad late-stage pipeline, the company is building several long-term growth initiatives intended to diversify future revenue streams.

Specification

Ticker	PFE
Exchange	NYSE
Sector	Large Pharma
Market Cap	$149.38B
Free Float	69.29%
ISIN	US7170811035

PFE 1Y Chart



**** For informational purposes only and should not be interpreted as investment recommendations or valuation opinions.*

Oncology: Expanding a Core Growth Platform

Oncology has become a major strategic focus following Pfizer's acquisition of Seagen, strengthening its capabilities in antibody-drug conjugates and targeted cancer therapies. The transaction broadened the company's portfolio across several high-value oncology indications while adding complementary research and development capabilities. Recent regulatory milestones, including the approval of Tivdak in China, further expand Pfizer's international oncology presence and reflect continued investment in precision medicine and global commercialization.

Obesity: Building a Presence in a Rapidly Growing Market

Pfizer is expanding its obesity and metabolic disease portfolio through berobenatide and related pipeline assets. The company is developing therapies with the potential for monthly maintenance dosing, representing a differentiated approach within the GLP-1 market. Recent acquisitions and business development initiatives demonstrate management's commitment to establishing a long-term position in obesity and cardiometabolic disease, supported by Pfizer's global manufacturing and distribution capabilities.

Artificial Intelligence and Innovation

Artificial intelligence is becoming an increasingly important component of Pfizer's operating model. The company is deploying AI across research, clinical development, manufacturing, and commercial operations to accelerate drug discovery, improve decision-making, and enhance productivity. These initiatives are intended to streamline development processes and strengthen operational efficiency as pharmaceutical research becomes increasingly data-driven.

Financial Position

Pfizer continues to generate significant cash flow while maintaining substantial investment in research and development. During the first quarter of 2026, revenue increased to $14.45 billion, and operating cash flow reached approximately $2.62 billion, supporting continued investment in acquisitions, pipeline expansion, and innovation. The company also strengthened its liquidity position while modestly reducing long-term debt.

Key Financials Stats: Quarterly

In Millions, USD	2026 Q1	2025 Q1
Revenue	14,451	13,715
Gross Profit	11,044	11,123
EBITDA	6,692	6,756
Net Income	3,523	4,355
EPS	0.61	0.76
Cash From Operations	2,615	2,335
Capex	-436	-564
Free Cash Flow	2,179	1,771

Key Financials Stats: Annuals

In Millions, USD	2022	2023	2024	2025
Revenue	100,330	59,554	63,627	62,579
Gross Profit	66,233	35,565	47,207	47,439
EBITDA	43,892	12,864	24,343	25,431
Net Income	35,536	7,005	13,097	19,889
EPS	6.20	1.22	2.30	3.49
Cash From Operations	29,267	8,700	12,744	11,704
Capex	-3,236	-3,907	-2,909	-2,501
Free Cash Flow	26,031	4,793	9,835	9,075

*** *Financial metrics and valuation information are provided solely for informational purposes and should not be interpreted as investment recommendations or valuation opinions.*

Key Multiples

Ratio	2022	2023	2024	2025	Current - Q1 26
P/E	8.27	23.54	11.53	7.14	8.57
P/B	3.01	1.83	1.70	1.64	1.66
P/Sales	2.86	2.73	2.36	2.26	2.35
ROA	16.57%	1.00%	3.65%	3.69%	3.60%
ROE	36.30%	2.29%	9.06%	8.90%	8.30%

Valuation Snapshot

Pfizer currently trades at approximately 8.57x earnings, 8.86x forward earnings, 7.94x forward EV/EBITDA, and 3.26x forward EV/Sales. Relative to many large-cap pharmaceutical peers, these valuation metrics remain below sector averages while the company continues to advance initiatives across oncology, obesity, and digital transformation.

PFE vs Peers

Ticker	P/E	FWD P/E	FWD EV/EBITDA	FWD EV/SALES
PFE	**8.57**	**8.86**	**7.94**	**3.26**
BMY	9.63	9.05	8.60	3.22
ABBV	22.35	15.97	14.16	6.93
LLY	38.51	31.29	25.30	12.29

**** Financial metrics and valuation information are provided solely for informational purposes and should not be interpreted as investment recommendations or valuation opinions.*

WEEKLY IDEA

15 June 2026

AGC
Arabian Gulf Capital

PFE Blended Forward P/E vs Peers



PFE Blended Forward EV/EBITDA vs Peers

**** Financial metrics and valuation information are provided solely for informational purposes and should not be interpreted as investment recommendations or valuation opinions.*

Key Risks

Pfizer operates in highly competitive therapeutic markets where clinical outcomes, regulatory approvals, pricing dynamics, and commercialization success can materially influence future performance. Continued normalization of COVID-related revenues, patent expirations, and increasing competition in obesity and oncology also remain important considerations. However, the company's diversified portfolio, global scale, and ongoing investment in research and development provide resources to navigate these evolving industry dynamics.

Summary

Pfizer is undergoing a broad strategic transformation centered on oncology, obesity, artificial intelligence, and next-generation therapeutics. Through acquisitions, internal research, and operational modernization, the company is expanding its capabilities across several areas of long-term healthcare innovation while leveraging one of the largest commercial and manufacturing platforms in the industry.

As these initiatives continue to develop, Pfizer remains a notable participant in several of the pharmaceutical sector's most important growth themes, supported by significant scale, diversified operations, and continued investment in research and innovation.

- *Source: Public company filings, Bloomberg, market data providers, and publicly available information as of the date of publication.*
- *This material is provided for informational purposes only and does not constitute independent investment research, investment advice, or a recommendation to buy or sell any financial instruments.*
- *Investments in equity securities are subject to market risk, sector risk, liquidity risk, and issuer-specific risks which may result in partial or total loss of invested capital.*

Disclaimer

Arabian Gulf Capital BSC (Closed) is licensed and regulated by the Central Bank of Bahrain (CBB) as a Bahraini Investment Firm (Category 1). Office Address: Office No. 3201, Building 01, Isa AlKabeer Avenue, Bahrain World Trade Center, Block 316, Manama, Kingdom of Bahrain. This communication is provided for informational purposes only and is not directed at retail investors. Certain products and services referenced may only be available to Expert and Accredited Investors in accordance with applicable CBB rules and regulations. The fees and tariffs mentioned in this document are provided for informational purposes only and are subject to change at the discretion of Arabian Gulf Capital BSC (Closed). Additional charges such as VAT, duties, and other external fees may apply. Clients are advised to review the latest tariff schedule and consult with their relationship manager for any clarifications. This document does not constitute an offer, solicitation, or recommendation to transact in any securities or investment products. All investments carry risks, and past performance is not indicative of future results. Clients should consider their individual circumstances and seek independent advice before making investment decisions. For further details or inquiries, please contact Arabian Gulf Capital BSC (Closed) directly.